An HIV vaccine candidate developed at the Duke Human Vaccine Institute has demonstrated the ability to trigger low levels of a rare type of neutralising antibodies (bnAbs) in a small group of participants.
The future of HIV and sexual health services is far from certain, says Debbie Laycock, Head of Policy and Parliamentary Affairs at Terrence Higgins Trust
Better understanding of the factors at play will enable efforts to reduce HIV transmission in Southern and Eastern Africa, where incidence rates are highest
The...
Gabriel Wikström, Minister for Health Care, Public Health and Sport, sets out the Swedish agenda to end AIDS by 2030 to Open Access Government
Today...
Although there are many reasons to celebrate the life-extending benefits from antiretroviral therapeutics (ART) for HIV/AIDS and the ability to chronically manage patients’ disease...
Professor Tomáš Hanke of the Jenner Institute, University of Oxford discusses why the development of HIV-1 vaccine remains a high global health priority
Since the...
